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A variety of rare clinical syndromes are seen with strikingly increased prevalence in HIV-1-infected individuals, many with underlying viral
etiologies. The emergence of these diseases in AIDS reflects a reduction in the ability of the immune system to mount an adequate defense against
viruses in general due to the damage inflicted to the immune system by HIV-1 infection. However, in many cases, it has been found that HIV-1 can
enhance the level of expression and hence the life cycle of other viruses independently of immunosuppression through specific interactions with
the viruses. This can occur either directly by HIV-1 proteins such as Tat enhancing the activity of heterologous viral promoters, and/or indirectly
by HIV-1 inducing the expression of cytokines and activation of their downstream signaling that eventually promotes the multiplication of the
other virus. In a reciprocal manner, the effects of other viruses can enhance the pathogenicity of HIV-1 infection in individuals with AIDS through
stimulation of the HIV-1 promoter activity and genome expression. The purpose of this review is to examine the cross-interactions between these
viruses and HIV-1.
© 2006 Elsevier Inc. All rights reserved.Keywords: HIV-1; Tat; Transactivation; PromotersIntroduction
Human immunodeficiency virus-1 (HIV-1) is the etiological
agent of acquired immunodeficiency syndrome (AIDS). HIV-1
is a retrovirus with a 9181-bp genome encoding three groups of
structural proteins, gag, pol, and env. In addition, the HIV-1
genome encodes several small regulatory/accessory proteins,
including vpu, vpr, tat, nef, vif, and rev (reviewed in Frankel and
Young, 1998; Seelamgari et al., 2004; Li et al., 2005). Morbidity
and mortality rates from AIDS have dramatically decreased in
areas of the world where highly active antiretroviral therapy
(HAART) is available (Richman, 2001; Cohen, 2002). However,
HIV-1 infection and progression to AIDS still remains a major
problem in poorly resourced parts of the world where HAART is
not fully available (reviewed in Armstrong et al., 2005). Co-
infection with other opportunistic pathological agents continues
to be a significant problem (Del Valle and Piña-Oviedo, 2006).
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doi:10.1016/j.virol.2006.04.006cystis pneumonia, protozoans, e.g., leshmaniasis and viruses.
Opportunistic viral infections occurring in AIDS patients
include cytomegalovirus (CMV) (Wilson, 1992; Roels, 2004),
Epstein–Barr (EBV) (Schulz et al., 1996; Knowles, 1996),
KSHV/HHV-8 (Aaron et al., 2004; Desjeux and Alvar, 2003;
Orem et al., 2004) and JC virus (JCV) (Khalili et al., 2004;Wyen
et al., 2004). These viruses and others are discussed in the
sections below.
It has been found that HIV-1 can enhance the pathogenicity
of other viruses, not only by inducing an immunosuppressed
state in which the host defensive responses to virus are muted,
but also by specific enhancement of viral replication by HIV-1
gene products. A major contributor of this type is the HIV-1
transcriptional transactivator Tat (Li et al., 2005; Peruzzi,
2006). It is believed that there are two ways in which Tat may
act to exert its effects on the expression of other viral genomes
and their life cycles. Firstly, Tat can act directly on
heterologous viral promoters to transactivate their transcrip-
tion. Examples of this are provided by viruses such as CMV
and JCV as described below. Tat is a powerful stimulator of
JCV transcription (Krachmarov et al., 1997; Wortman et al.,
2000; Johnson, 2003; Mischitelli et al., in press) and
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the cellular transcription factor Purα to increase JCV gene
expression by interacting with the JCV non-coding regulatory
region. Secondly, Tat can indirectly affect the life cycle of other
viruses through its ability to alter the transcription of certain
cytokines, e.g., Tat interacts with the cellular cyclin T1/cdk9
complex and Purα at the cellular TNF-α promoter to stimulate
expression of the cytokine TNF-α (Darbinian et al., 2001).
TNFα is an activator of the NF-κB signaling pathway. In turn,
activation of the NF-κB signaling pathway can activate
transcription of JCV (Safak et al., 1999). These phenomena
are discussed in more detail below.
The interaction of HIV-1 with other viruses is reciprocal in
that the effects of other viruses can enhance the pathogenicity of
HIV-1. For example, transcription from the HIV-1 LTR is
transactivated by several types of DNA viruses including JCV,
BK virus (BKV), herpes simplex virus type I (HSV-1),
adenovirus and varicella zoster as will be discussed below.
Additionally, HIV-1 LTR transcription can be stimulated by
other human retroviruses including HTLV-I and this will also be
discussed. In this review, we will consider the HIV-1 protein Tat
and how this protein moderates communication with the
promoter of HIV-1 itself, cellular promoters and the promoters
of other viruses. We will also discuss the reciprocal interaction
of HIV-1 with other viruses for each of the types of virus for
which this type of interaction has been shown to occur.
HIV-1 Tat
The HIV-1 Tat gene encodes a two-exon protein of 86 to 101
amino acids in length that is required for virus replication and is
conserved in all primate lentiviruses (Jeang et al., 1999; Giacca,
2004). Amino acids 1–72 and 73–101 are encoded by two
separate exons. The main function of Tat is to activate efficient
transcription elongation from the HIV-1 long terminal repeat
(LTR) (Karn, 1999; Pumfery et al., 2003). In the absence of Tat,
initiation of transcription from the HIV-1 LTR is efficient, but
RNA polymerase terminates transcription prematurely. Efficient
elongation occurs only in the presence of Tat, which binds to a
short nascent stem-bulge-loop leader RNA termed TAR, for
transactivation response element. Upon binding to the TAR
element, a ternary complex consisting of Tat and two cellular
proteins, cyclin T1 and cdk9, are brought into close proximity to
RNA polymerase II, resulting in hyperphosphorylation of the C-
terminal domain (CTD) of RNA polymerase II by cdk9.
Hyperphosphorylation of the CTD of RNA polymerase II
allows for efficient elongation of nascent HIV-1 RNA
transcripts (Karn, 1999; Pumfery et al., 2003).
Tat utilizes many pathways, both direct and indirect, to
affect transcription from heterologous promoters. Tat activates
transcription of several cytokines that are released and can act
via autocrine and paracrine pathways to affect transcription
(Rappaport et al., 1999, Reinhart, 2003). Examples include
tumor necrosis factor-α (Biswas et al., 1995; Darbinian et al.,
2001; Contreras et al., 2005), IL-2 (Kumar et al., 2005), IL-6
(Scala et al., 1994), IL-10 (Contreras et al., 2004), MCP-1
(Abraham et al., 2003, 2005), TGF-β(Cupp et al., 1993; Zauliet al., 1992; Enam et al., 2004), XCL1 (Kim et al., 2004),
CCL2, CXCL8, CXCL10, CCL3, CCL4, and CCL5
(D'Aversa et al., 2004). Tat also has been shown to activate
transcription by binding to TAR-like sequences in the 5′-
untranslated region of nascent RNA of several genes
including IL-6 (Ambrosino et al., 1997) and TNF-β
(Buonaguro et al., 1994). Tat can also interact with DNA-
bound transcription factors and be brought into proximity of
the transcription initiation machinery without having to bind
to RNA. An example of this is the studies in which Tat has
been shown to transactivate the JCV late promoter by binding
to the promoter-bound cellular transcription factor Purα (see
below; Krachmarov et al., 1997). The role of cytokine and
chemokine induction in the life cycle of HIV-1 has been
reviewed recently (Reinhart, 2003) and a more general review
on viral exploitation and subversion of the immune system is
also available (Murphy, 2001). As regards the role of cytokine
and chemokine induction in the interaction with other viruses,
available information from the literature has been included in
the sections below for each particular virus.
In addition to its effects on gene transcription, Tat also has
several other functions including the activation of T-lympho-
cytes (Ott et al., 1997; Pessler and Cron, 2004), activation or
inhibition of apoptosis depending on the cell type (Zauli and
Gibellini, 1996; Selliah and Finkel, 2001; Gulow et al., 2005;
Peruzzi, 2006), and has also been shown to have growth factor
and angiogenesis-inducing activities (Ensoli et al., 1990;
Barillari and Ensoli, 2002; Bergonzini et al., 2004). Tat also
affects antigen recognition by targeting dendritic cells and
increasing their antigen presentation function biasing towards
the Th1 response, and regulates the immunoproteasome subunit
composition to affect antigen processing, increasing the
generation and presentation of subdominant MHC-I cytotoxic
T-lymphocyte epitopes (Gavioli et al., 2004).
It has been found that Tat has the unusual property of being
released from HIV-1-infected cells and taken up again by
neighboring cells ( Ensoli et al., 1993;Frankel and Pabo, 1988).
For example, astrocytes producing Tat release it extracellularly
where it can stimulate transcriptional transactivation of the HIV-
1 LTR in lymphocytic and astrocytic cell lines (Chauhan et al.,
2003). Thus, the effect of Tat on the life cycle of other viruses
need not require the coinfection of the same cells with both
viruses.
Cytomegalovirus
Reactivation of cytomegalovirus (CMV) in AIDS patients
can affect a variety of organ systems. CMV retinitis is the most
common retinal opportunistic infection in patients with AIDS,
which if left untreated leads to progressive loss of vision
(Wilson, 1992; Roels, 2004). Several other CMV-related
complications including colitis, esophagitis, gastritis, and
lumbosacral polyradiculopathy (Balthazar et al., 1985; Theise
et al., 1991; Laguna et al., 1993; Anders and Goebel, 1998)
have been described. Furthermore, it has been suggested that
CMV acts as a cofactor for HIV, accelerating progression to
clinical AIDS (Webster, 1991).
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between CMV and HIV in the pathogenesis of AIDS. Davis et
al. noted that more than 95% of homosexual men at risk for
AIDS are seropositive for hCMV. Elevated titers of anti-CMV
antibody significantly predicted the development of AIDS in
homosexual men (Polk et al., 1987). It has also been shown by
Webster (1991) that coinfection with CMV in hemophiliacs
increased the relative risk of developing AIDS 2.5 times when
compared to HIV positive individuals seronegative for CMV
infection.
One potential mechanism for cooperativity between CMV
and HIV is that gene products encoded by CMV affect the
transcription of the HIV genome, and vice versa. In fact,
coinfection of cells with HIV-1 and CMV enhances productive
infection by both HIV-1 and CMV (Skolnik et al., 1988; Ho et
al., 1990). Davis et al. (1987) showed that the immediate early
(IE) gene region of CMV transactivates the HIV long terminal
repeat. In particular, region 2 (IE2) of the immediate early
region of CMV contained the transactivation activity. Further-
more, they show that the region of the HIV LTR required for
transactivation by IE2 of CMV is distinct from that required by
HIV Tat. Infection of cells transfected to express HIV Tat with
CMV leads to enhanced immediate early gene expression and
higher CMV DNA levels (Ho et al., 1990). Infection of human
rhabdomyosarcoma cells constitutively expressing Tat with
CMV showed enhanced IE and late proteins, while transfection
of these same cells with a CMV-immediate early gene reporter
showed increased transcriptional activity in response to Tat (Ho
et al., 1991). When human osteosarcoma cells engineered to
contain an envelope-deficient HIV-1 proviral construct (HOS-
HGX cells) were infected with CMV, they showed increased
numbers of intranuclear nucleocapsids when compared to
control cells (HOS cells) (Margalith et al., 1993). Furthermore,
infectious CMV was persistently detected in the supernatant
from CMV-infected HOS-HGX, but gradually declined from
the supernatant of control HOS cells over a period of several
weeks. Superinfection of the CMV-HOS-HGX cells on day 119
with HIV-1 produced enhanced levels of CMV replication
greater than control CMV-infected HOS-HGX cells. Finally,
inhibition of Tat with antibodies to the Tat protein did not inhibit
the replication of CMV in the HOS-HXG cells, suggesting that
factors other than Tat may play a role in HIV-1-induced
enhancement of CMV replication. Lazzarotto et al. (1994)
infected a CD34+ hematopoietic progenitor cell line (TF1) with
hCMV and found that addition of exogenous Tat protein
stimulates hCMV replication. In contrast, they found that
addition of HIV gp120 to hCMV-infected cells inhibited hCMV
replication. Although the results of Lazzarotto et al. contrast
sharply with the repeat of Margalith et al. with respect to the Tat,
differences may be explained by the experimental systems used.
Further evidence for cooperation at the molecular level
between CMV and HIV-1 comes from studies by Dal Monte et
al. (1997). They determined that hCMV IE2 enhances Tat-
dependent LTR transcription through the TATA binding region
of IE2. Synergism between IE2 and Tat occurs on both Sp1-
binding site-deleted and TAR-deleted LTR, indicating a
possible molecular mechanism by which Tat and IE2 can playa role in HIVactivation when cells are coinfected with both HIV
and CMV.
KSHV
Kaposi's sarcoma-associated herpesvirus (KSHV; also
known as human herpesvirus-8) is a γ-herpesvirus that has
been associated with all forms of Kaposi's sarcoma (KS), as
well as two other neoplastic disorders: multicentric Castelman's
disease and primary effusion lymphoma (reviewed in Gruffat et
al., 2000; Bryan et al., 2005). KHSV has a 165-kb genome and
maintains a state of latency in B-cells. Of note, numerous
KSHV genes encode proteins with striking homology to cellular
proteins that may play a role in the pathogenesis of KSHV-
associated disease including an interleukin-6 homolog (v-IL-6),
β-chemokine (v-MIP), cellular cyclin D (v-cyclin), G-protein
coupled receptor (v-GPCR), and the viral protein v-FLIP
(Cesarman et al., 1996; Chang et al., 1996; Moore et al., 1996;
Weiss et al., 1998).
KS is a highly vascularized multifocal tumor increased in
frequency in HIV-1-infected individuals (Ensoli et al., 2001;
Cheung, 2004). A mild form of KS occurs rarely in
immunocompromised transplant recipients (iatrogenic KS)
and Mediterranean Eastern-European elderly men (sporadic
KS) (Penn, 1979; Geddes et al., 1994). However, with the
advent of the AIDS era, a more highly aggressive form of KS,
AIDS-KS, became the most common neoplasm among HIV-1-
infected individuals (Ensoli and Sirianni, 1998). Unlike
iatrogenic and sporadic KS, which may regress, AIDS-KS is
highly aggressive and progresses very rapidly (Ensoli and
Sirianni, 1998). In 1994, KSHV was discovered and found to be
associated with KS lesions (Chang et al., 1994). Although
KHSV is present in all KS lesions, the virus alone is not
sufficient to cause KS tumor formation (Gallo, 1998b). Since
the late 1980s, it has been shown that several cytokines,
including interleukin-1 (IL-1), IL-6, and interferon-γ are able to
promote the formation of KS tumors (Gallo, 1998b; Ensoli et
al., 2001). Histologically, KS is a neoplasm of vascular origin
and consists of spindle-shaped cells, inflammatory cell
infiltration, vascular endothelial and smooth muscle cells,
fibroblasts, and neoangeogenesis (Gallo, 1998a; Rabkin et al.,
1997).
The fact that AIDS-KS occurs more frequently and in a more
aggressive form in HIV-1-infected individuals suggested that
HIV-1 gene products influence the progression and phenotype
of KS in AIDS. As discussed below, Tat has been shown to play
a significant role in several aspects of AIDS-KS development.
There are several pathways by which Tat affects the
development of highly aggressive AIDS-KS. First, Tat can act
as a growth factor for cells derived from KS lesions. Tat is
released from HIV-1-infected as well as Tat-transfected cells
and can stimulate the growth of cells derived from KS lesions of
AIDS patients (AIDS-KS cells) as well as cytokine-activated
normal vascular cells (Ensoli et al., 1990; Barillari et al., 1993).
Extracellular Tat cooperates with bFGF in promoting AIDS-KS
and endothelial cell growth to induce KS lesions in vivo, and
when combined with bFGF Tat acts to increase MMP-2 and
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ability (Ensoli et al., 1994). The importance of this observation
is re-enforced by the finding of increased MMP-2 expression in
AIDS-KS lesions (Toschi et al., 2001). Tat also promotes the
G1-S transition in endothelial cells (Fiorelli et al., 1995).
Tat also acts as a survival factor for AIDS-KS and
endothelial cells, up-regulating Bcl-XL expression and down-
regulating caspase-3 activity, and activates the PI-3-kinase-
dependent survival pathway (Cantaluppi et al., 2001; Deregibus
et al., 2002). By sustaining endothelial cell survival, Tat
contributes to tumor development. In fact, when introduced into
the germline of mice, the Tat gene induces dermal lesions highly
reminiscent of KS lesions (Vogel et al., 1988).
Tat has angiogenic properties as well, inducing the
adhesion, migration, and degradation of basement membrane
by AIDS-KS and normal vascular cells, an activity which was
shown to be dependent on the interaction between the RGD
motif of Tat and α5β1 and αVβ3 integrins (Barillari et al.,
1993; Albini et al., 1995). Tat induces the expression of the
cell adhesion molecules V-CAM-1 and I-CAM-1, and the
cytokines MCP-1 and IL-6 in AIDS-KS cells (Kelly et al.,
1998). Tat enhances the phosphorylation and association of
focal adhesion proteins such as RAFTK, paxillin, and
p130cas, and activates MAP kinase, JNK, and src kinase
(Ganju et al., 1998).
Lending further credence to the proposed role for Tat as a
cofactor in HIV-1-infected individuals responsible for inducing
the highly aggressive form of KS, Tat can activate KS cells
derived from sporadic and iatrogenic lesions (Morini et al.,
2000). Tat binds to and activates the Flk-1/KDR receptor for
VEGF that is expressed by KS cells from non-AIDS KS
(sporadic and iatrogenic KS) lesions and induces migration,
demonstrating Tat can act as a cofactor contributing to the
aggressiveness of AIDS-KS (Morini et al., 2000). This activity
of Tat is blocked with anti-KDR antibodies, reinforcing the
importance of the VEGF-A receptor in Tat-dependent effects on
KS cells (Morini et al., 2000).
Since the discovery of HHV-8, there have been several
observations that support a direct interaction between HHV-
8 and HIV-1 at the molecular level and correlate with the
unusually high incidence and aggressiveness of KS in HIV-1-
infected individuals. Infection of a primary effusion cell line,
which also harbors HHV-8, with HIV-1 leads to the
reactivation of latent HHV-8 (Merat et al., 2002). Further-
more, HIV-1 infection induces the secretion of cytokines and
soluble factors capable of inducing HHV-8 replication in
bystander cells, and induces HHV-8 lytic replication by
activating Rta/ORF-50 gene expression, which controls the
transition from latency to lytic replication (Varthakavi et al.,
2002). Transfection of a primary effusion lymphoma cell line
with Tat leads to the reactivation of latent HHV-8 (Merat et
al., 2002). The HHV-8-encoded G-protein coupled receptor
(vGCR) gene expression is activated by HIV-1 Tat, providing
a mechanism by which Tat can have tumorigenic and
angiogenic effects (Yen-Moore et al., 2000). Also, Tat and
Vpr both increase intracellular HHV-8-specific gene expres-
sion (Huang et al., 2001). There is also evidence for theactivation of HIV-1 LTR transcription by HHV-8 gene
products. HHV-8-encoded FLICE inhibitory protein (vFLIP)
activates the HIV-1 LTR by activating the NFκB pathway and
cooperates functionally with Tat (Sun et al., 2003). The KIE-2
immediate early gene product of HHV-8 acts synergistically
with Tat to activate the HIV-1 LTR (Huang et al., 2001).
In conclusion, Kaposi's sarcoma is a complex neoplasm, the
development of which is dependent upon infection with KSHV
and is greatly enhanced by HIV-1 Tat and cytokines involved in
chemoattraction, neovascularization and stimulation of HIV-1
replication.
HHV-6
Human herpes virus-6 (HHV-6) is a γ herpesvirus closely
related to HHV-7 (Caserta and Hall, 1998). HHV-6 infects
infants between the ages of 6 to 24 months, with a small
percentage developing roseola infantum (Dockrell et al., 1999).
HHV-6 causes disease in immunocompromised hosts, such as
HIV-positive individuals and transplant recipients (Lusso and
Gallo, 1995; Dockrell, 2003). HHV-6 infects a variety of human
cell types, with a major tropism for T-lymphocytes. HHV-6 has
a unique ability to avoid the host immune system. It does so by
inducing T lymphocyte depletion via apoptosis (Inoue et al.,
1997). HHV-6 also increases the degree of immunosuppression
of HIV-1-infected individuals (Lusso and Gallo, 1995). HHV-6
reactivation is frequently found associated with other viruses in
immunocompromised hosts including CMV and HIV (Lusso
and Gallo, 1995; Lautenschlager et al., 2000). In HIV-infected
individuals HHV-6 causes pneumonitis and encephalitis (Case-
rta et al., 2001).
Clinical and experimental evidence suggests that HHV-6
accelerates HIV-1 infection and progression to AIDS (for
review, see Lusso and Gallo, 1995). Active HHV-6 infection
occurs early on in HIV-1 disease progression and is believed to
act as a cofactor in progression to AIDS (Knox and Carrigan,
1996). HHV-6 infects many of the same cell types as HIV-1,
including T-cells, B-cells, and glial cells and like HIV-1 has a
primary tropism for CD4+ T lymphocytes (Garzino-Demo and
Gallo, 2003; Horvat et al., 1989; Lusso and Gallo, 1995). HHV-
6 and HIV-1 productively co-infect CD4+ T lymphocytes,
resulting in accelerated HIV-1 expression and resultant cellular
death (Lusso et al., 1989). HHV-6 coinfection can break HIV-1
latency leading to increased rate of HIV-1-dependent T-cell
death (Knox and Carrigan, 1996; Lusso et al., 1989). HHV-6
gene products synergize with Tat to activate HIV-1 LTR
transcription and can trigger HIV-1 activation (Ensoli et al.,
1989; Garzino-Demo et al., 1996; Horvat et al., 1989; Lusso et
al., 1989; Di Luca et al., 1991). Co-infection of cells with HHV-
6 and HIV-1 produces an increase in infectious HHV-6 titre,
HHV-6 immediate-early RNA, and an increase in HHV-6
protein synthesis (Sieczkowski et al., 1995). T-cells transfected
to express Tat and infected with HHV-6 produce higher levels of
HHV-6 proteins and infectious virus (Sieczkowski et al., 1995).
HHV-6 infection stimulates HIV-1 replication via transactiva-
tion of the LTR through the Sp1 binding sites in the HIV-1 LTR
(Wang et al., 1994). ORF-1 of HHV-6 also transactivates the
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contains the TATA box element, and reactivates tat-defective
provirus (Kashanchi et al., 1994). One HHV-6 gene product,
IE2, when transfected into T-cells, transactivates the HIV-1
LTR through CRE, NF-AT, and NFκB elements (Gravel et al.,
2003).
It has also been reported that HHV-6 induces production of
the cytokines CCL3 and CCL5 which may affect HIV-1
replication in coinfected human lymphoid tissue (Glass et al.,
2003).
In conclusion, molecular details are emerging about the
mechanisms whereby HHV-6 and HIV-1 co-operate with each
other in the pathogenesis of immunosuppressive disease.
HSV-1
Herpes simplex virus-1 (HSV-1) is a common co-infection in
HIV-1-infected individuals (Schacker, 2001). HSV-1 is a cause
of encephalitis and a frequent cause of oral ulcers in HIV-1-
infected individuals (Chretien et al., 1996; Itin and Lautens-
chlager, 1997). There is evidence that HSV-1 may interact with
HIV-1 to influence HIV-1 disease progression (Palu et al.,
2001).
HSV-1 infection stimulates expression of the HIV-1
provirus (Schafer et al., 1996). HHV-1 cooperates with Tat
to activate transcription from the HIV-LTR (Gendelman et al.,
1986). Tat-independent transcription of the HIV-1 LTR is
important prior to accumulation of biologically significant
levels of Tat protein in cells. HSV-1 infection stimulates
transcription of a Tat-defective provirus, but in the absence of
Tat, the mRNA is not translated, indicating that HSV-1
infection alone is not sufficient to induce HIV-1 replication
(Popik and Pitha, 1994). Hence, Tat appears to play a critical
role in reactivation of HIV-1 provirus by HSV-1. HSV-1
immediate early gene products stimulate expression of the
HIV-1 LTR and replication of HIV (Ostrove et al., 1987;
Schafer et al., 1996). ICP0 and ICP4 stimulate the HIV-1
LTR in the absence and presence of Tat, and stimulate
replication of HIV in the presence of Tat (Ostrove et al.,
1987; Chapman et al., 1991). Therefore, ICP0 and ICP4 have
the potential to activate silent proviral HIV. ICP0 stimulates
transcription of a TAR-defective provirus, cooperating with
Tat by recruiting Tat to the LTR by providing an alternate
binding site (Schafer et al., 1996). HSV-1 targets regions of
the HIV-1 LTR distinct from Tat-responsive area and is close
to the Sp1 binding sites (Ostrove et al., 1987). Thus,
transactivation of the HIV-1 LTR can be mediated through
different HSV-1 gene products and also can be stimulated by
cytokine release and antigen presentation from HSV-infected
cells (Palu et al., 2001).
EBV
Epstein–Barr virus (EBV) is a γ herpesvirus with a genome
of ∼170 kb in length encoding approximately 80 open reading
frames (Baer et al., 1984). Primary infection with EBV induces
a transient lymphoproliferation, infectious mononucleosis, afterwhich EBV maintains a state of latency in the B-lymphocyte
compartment (List et al., 1987; reviewed in Ambinder, 2001). In
immunosuppressed hosts, such as transplant recipients receiv-
ing immunosuppression therapy and HIV-1 infected indivi-
duals, EBV induces a variety of hyperproliferative B-
lymphocyte disorders which can result in B cell malignancies
(List et al., 1987; MacMahon et al., 1992). EBV infection has
been associated with several tumors including B- and T-cell
lymphomas, Hodgkin's disease, nasopharyngeal carcinoma and
Burkitt's lymphoma (reviewed in Ambinder, 2001). EBV-
infected HIV-1-positive individuals have increased incidence of
non-Hodgkin lymphomas including Burkitt's lymphoma
(Schulz et al., 1996; Knowles, 1996).
HIV-1-infected individuals show a high incidence of
infection with EBV (Scala et al., 1993). The immediate early
gene product, MLF1, stimulates LTR transcription. This activity
does not require the Tat-responsive region, and occurs via a
post-transcriptional mechanism (Kenny et al., 1988). The
immediate early gene product BZLF1 transactivates the LTR
and synergizes with Tat (Mallon et al., 1990). The latent
membrane protein, LMP, transactivates the LTR through the κB
site, and synergizes with Tat even in the absence of TAR
(Hammarskjold and Simurda, 1992). EBNA2 transactivates the
LTR by activation of NF-κB and depends on the κB and Sp1
binding sites, and enhances Tat dependent LTR transcription
(Scala et al., 1993; Zhang et al., 1997).
It has been reported that Tat may modulate the level of the
cytokine MIP-1α and its receptors in human B-cells derived
from patients with AIDS and Burkitt's lymphoma. This may
represent another mechanism of cross-talk between HIV-1 and
EBV (Sharma et al., 1997).
In conclusion, EBV is a significant factor in some AIDS-
associated malignancies and further research into the interac-
tions between these two viruses is warranted.
JC virus (JCV)
JCV is one of three polyomaviruses that can infect
humans, the others being BKV and SV40. These are non-
enveloped tumor viruses with icosahedral capsids containing
small, circular, double-stranded DNA genomes. The circular
JCV genome encodes only six proteins contained within two
regions of about the same size; the early and late transcription
units. Since JCV requires the host DNA synthesis machinery
to replicate, it must drive the cell into S-phase and this is
achieved through the action of the early protein, large T-
antigen, which functions by binding to p53, pRb and other
cell regulatory proteins (reviewed in White and Khalili,
2004a,b, 2005). JCV is the etiological agent of a rare
demyelinating disorder of the central nervous system,
progressive multifocal leukoencephalopathy (PML), charac-
terized by infection and lytic replication of JCV in
oligodendrocytes and subsequent cell lysis and loss of
myelination of cortical neurons (Gordon and Khalili, 1998;
Khalili et al., 2004). The occurrence of PML was very rare
until the advent of the AIDS pandemic but now it is much
more prevalent and affects ∼5% of HIV-infected persons
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incidence of PML in most immunosuppressive conditions,
there is a strikingly higher incidence of PML in AIDS
patients compared to patients incurring immunosuppression
from other causes (relative to their frequencies). The high
incidence of PML complicating HIV/AIDS compared to other
immunosuppressive disorders suggested an interaction be-
tween HIV-1 and JCV. In 1990, Tada et al. showed that the
HIV-1 Tat protein can transactivate the late promoter of JCV
in glial cells (Tada et al., 1990), while the JCV early gene
product T antigen transactivates the HIV-1 LTR (Gendelman
et al., 1986). This reciprocal interaction between HIV-1 and
JCV gene products was suggested as a possible contributory
mechanism explaining increase JCV lytic replication in glial
cells with resultant cell death, ultimately manifesting as PML.
Tat and JCV T antigen synergize to activate the late promoter
of JCV through distinct target sequences in the JCV promoter
(Chowdhury et al., 1990). A sequence similar to HIV TAR is
required for Tat-dependent induction of JCV late promoter
transcription (Chowdhury et al., 1992). An RNA sequence in
the 5′ untranslated region of JCV late transcripts shares
extensive homology to the HIV TAR sequence, and through
mutagenesis critical G residues which are found within the
HIV TAR element were shown to exist in JCV TAR and to
be vital for Tat-dependent JCV late activity (Chowdhury et
al., 1992). Regions upstream of the late transcription start site
were also shown to be critical for Tat activation of the JCV
late promoter. These DNA motifs, termed upTAR, are GA/
GC-rich sequences that confer Tat responsiveness to heterol-
ogous promoters (Chowdhury et al., 1993). Further work
showed that the upTAR sequence is bound by the cellular
protein Purα. Tat physically interacts with Purα, enhances
binding of Purα to the upTAR element, and functionally
interacts synergistically with Purα to activate upTAR-
dependent transcription (Krachmarov et al., 1997). Tat can
also affect JCV DNA replication. Tat and Purα also cooperate
to induce JCV DNA replication via Purα binding close to the
origin of replication (Daniel et al., 2001). Exogenous Tat is
able to enter oligodendroglioma cells and activates JCV DNA
replication (Daniel et al., 2004). In clinical samples, the JCV
VP1 protein is detectable in oligodendrocytes in the absence
of HIV-1 p24 protein, but in the presence of Tat, supporting
the notion that Tat released from HIV-1-infected cells is
released in a biologically active form and enter non-HIV-1-
infected neighboring cells and affect JCV transcription and
replication (Del Valle et al., 2000).
Activation of JCV in AIDS patients may also involve
indirect mechanisms including the alteration of cytokine
profiles in HIV-1 infection. Many cytokines activate upstream
kinase signaling pathways that result in the activation and
nuclear translocation of NF-κB. Activation of the NF-κB
signaling pathway has been shown to enhance the transcription
of JCV (Safak et al., 1999). An example of such an indirect
cytokine pathway is TNF-α. Tat in conjunction with the cellular
cyclin T1/cdk9 complex and Purα activates the cellular TNF-α
promoter to stimulate expression of the cytokine TNF-α
(Darbinian et al., 2001).BK virus (BKV)
In recent years, opportunistic BKV reactivation has been
shown to be involved in a growing list of complications in
HIV-1-infected individuals. Examples include meningoenceph-
alitis (Vallbracht et al., 1993; Garavelli and Boldorini, 2002),
atypical retinitis (Hedquist et al., 1999), nephritis (Nebuloni et
al., 1999; Smith et al., 1998), hemorrhagic cystitis (Gluck et
al., 1994), pneumonitis (Cubukcu-Dimopulo et al., 2000), and
disseminated infection involving multiple organs (Bratt et al.,
1999; Vallbracht et al., 1993). Furthermore, several studies
have shown increased detectable levels of BKV in AIDS
patients (Markowitz et al., 1993; Knowles et al., 1999; and
Pietropaolo et al., 2003). In addition, the degree of BKV
reactivation was shown to correlate with the severity of
immunodeficiency (Markowitz et al., 1993; Knowles et al.,
1999). These observations suggested an interaction between
HIV-1 and BKV.
In fact, Tat dramatically increases transcriptional activity of
the BKV early promoter (BKVE) that is responsible for
producing the viral early protein T-antigen (Gorrill and Khalili,
2005; Gorrill et al., in press). Tat activates the BKVE promoter
by inducing the binding of the p65 subunit of NFκB to a κB
motif on the early side of the BKV promoter and also by binding
to an RNA binding site (BKVE-TAR) within the 5′ untranslated
region of BKVE transcripts with a sequence identical to the
bulge of the HIV TAR. Mutations in either the κB motif or
BKVE-TAR prevent the stimulation of the BKVE promoter by
Tat suggesting that these two sites co-operate to induce
transcriptional transactivation (Gorrill et al., in press). As
regards the activation of the BKV promoter through the BKVE
κB site, this may occur by a direct or indirect mechanism. Direct
interaction between NF-κB is involved in TAR-independent
activation of the HIV-1 LTR in cells from the CNS (Taylor et al.,
1995) and may involve a third protein named NFBP (Sweet et
al., 2005). With respect to an indirect interaction of Tat and NF-
κB, it has been previously demonstrated that Tat induces the
expression of TNF-α (Buonaguro et al., 1992; Darbinian et al.,
2001; Rautonen et al., 1994; Sawaya et al., 1998) which can
activate the NF-κB pathway (reviewed by Chen and Goeddel,
2002).
As was the case with JCV described in the previous section,
the early region protein, large T-antigen of BKV is able to
stimulate transcription from the HIV-1 LTR indicating mutual
cooperativity between BKV and HIV-1 (Gendelman et al.,
1986).
Adenovirus
The adenovirus early region encodes the proteins E1A and
E1B, which serve to drive the host cell cycle into S-phase by
their interaction with pRb and p53 respectively (Whyte et al.,
1988; Sarnow et al., 1982). The 13S form of the E1A protein
stimulates transcription from the HIV-1 LTR and this is
dependent on the presence of the TATA box (Nabel et al.,
1988; Rice and Mathews, 1988). When combined together,
E1A and Tat have a synergistic effect on HIV-1 LTR
Fig. 1. Molecular interactions of HIV-1 with other viruses. HIV-1 regulatory
proteins interact with cellular regulatory proteins to directly impinge on the life
cycle of other viruses, e.g., Tat binds the Purα transcription factor and thereby
transactivates the transcriptional control region of the JCV small DNA virus
(Krachmarov et al., 1997). Reciprocally, regulatory proteins of other viruses can
transactivate the HIV LTR, e.g., HIV LTR transcription is stimulated by JCV
large T-antigen and by regulatory proteins produced by several other types of
DNA viruses (Gendelman et al., 1986). Another mechanism of interplay
between viruses is the ability of regulatory proteins of HIV-1 and other viruses to
interact with cellular regulatory proteins and advance the cell cycle, pushing the
cell cycle towards S-phase to enable viral replication. For example, HIV-1 Tat
regulates cellular pathways that control the cell cycle and apoptosis (reviewed
by Peruzzi, 2006), and so does JCV T-antigen (reviewed by White and Khalili,
2004a,b, 2005). In addition, indirect mechanisms exist whereby viruses
modulate production of cytokines. These cytokines bind their cognate receptors
and modulate downstream signal transduction pathways regulating transcrip-
tion, e.g., Tat activates transcription of several cytokines (see text) that are
released and then act via autocrine and paracrine pathways to regulate
transcription. Finally, HIV-1 causes immunosuppression and thereby eliminates
the capacity of the immune system to fight opportunistic infection by many
pathogens including other viruses.
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initiation and on stabilization of transcriptional elongation
(Laspia et al., 1990). The molecular mechanisms of E1A
action are complex and differ for the 13S and 12S forms of
E1A implicating different domains within the protein and
involving interactions with pRb, TBP, TAFs, p300 and NF-κB
(Parker et al., 1997).Fig. 2. Interaction of HIV-1 with other viruses: diseases associated with specific virus
list of their pathologies. In some cases, the development of disease involves the eme
e.g., BKVand JCV. In other cases, the development of disease involves the transmiss
the immunosuppressed patient is vulnerable.HTLV-I
HTLV-I is a human retrovirus and the etiological agent of
adult T-cell leukemia/lymphoma (ATLL) and is also associated
with cutaneous T-cell lymphoma (CTCL). While most HTLV-I-
infected individuals remain asymptomatic carriers, 1–5% will
develop ATLL, an invariably fatal expansion of virus-infected
CD4+ T cells (Nicot, 2005). The finding of dual HTLV-I and
HIV-1 infections in populations at risk for AIDS raises the
possibility that interaction between the two viruses might have
clinical significance. Indeed superinfection studies demonstrat-
ed that HTLV-1 activates transcription from the HIV-1 LTR (De
Rossi et al., 1991). HTLV-I stimulation of the HIV-1 LTR
promoter is mediated by the HTLV-I protein Tax (Bohnlein et
al., 1989; Cheng et al., 1998; Moriuchi and Moriuchi, 2000).
The site within the HIV-1 LTR for Tax activation is distinct from
that for Tat (Zimmermann et al., 1991) and involves activation
of NK-κB through Tax-mediated degradation of I-κBβ (Good
and Sun, 1996). Tax also upregulates expression of the CXCR4
promoter and since CXCR4 is a co-receptor for T cell-tropic
HIV-1, this may also be a mechanism for promoting HIV
progression in co-infected individuals (Moriuchi et al., 1999).
Like Tat, Tax also affects the expression of a variety of cellular
genes and this reflects a complex interplay between a retroviral
regulatory gene and cellular gene regulation (reviewed by
Rosenblatt et al., 1995). Finally, it has been reported that the
interaction between HTLV-I and HIV-1 is indeed reciprocal and
that HTLV-I expression is increased with HIV-1 coinfection
(Beilke et al., 1998).
HIV-1 Vpr
HIV-1 Vpr (viral protein R) is a 96 amino acid 15 kDa
protein that increases the rate of viral replication and accelerateses. Specific viruses are associated with AIDS and these are shown followed by a
rgence of virus from a state of latency under conditions of immunosuppression,
ion of an infectious agent which then causes an opportunistic infection to which
8 M.K. White et al. / Virology 352 (2006) 1–13the cytopathic effect of the virus in T cells. Similarly to Tat, Vpr
acts in trans to increase levels of viral protein expression and has
a stimulatory effect on the HIV-1 LTR as well as on several
heterologous promoters (Cohen et al., 1990). Vpr is a virion-
associated protein that travels to the nucleus and has multiple
activities including virion packaging, promoter activation, cell
cycle arrest and induction of apoptosis (reviewed in Kino and
Pavlakis, 2004; Amini et al., 2004). The mechanism of HIV-1
LTR transactivation by Vpr involves interaction with several
cellular regulatory proteins including p53 (Sawaya et al., 2000),
p300/CBP (Kino et al., 2002), TFIIB (Agostini et al., 1996),
Sp1 (Wang et al., 1995; Sawaya et al., 2000). The stimulation of
HIV-1 LTR transcription by Vpr is synergistic with that of Tat
(Sawaya et al., 2000). Unlike Tat, relatively little is known
about transactivation of heterologous viral promoters by Vpr.
In Kaposi's sarcoma, Tat and Vpr proteins increase intracellular
HHV-8-specific gene expression (Huang et al., 2001). Vpr and
adenovirus E1A compete for the same binding site on the p300
cellular regulatory protein (Kino et al., 2002). In cervical
cancer cells, Vpr and human papilloma virus type 16 E6
protein have exacerbating effects on G2-phase arrest suggest-
ing that they share links in cell cycle signaling pathways (Toy
et al., 2000). It is possible that there exists interactions between
HIV-1 and other viruses that are mediated by Vpr but await to
be discovered.
Concluding remarks
HIV-1 devastates the immune system leaving the body open
to a broad range of opportunistic infections and this includes a
general susceptibility to viruses. However, investigations into
many types of viral infection have revealed specific reciprocal
interactions between HIV-1 and other viruses that go beyond
immunosuppression. Research over the last two decades has
led to the elucidation of many of the molecular mechanisms
underlying the increased incidence of several rare viral
etiologies in HIV-1-infected individuals. This research has
included methodologies ranging from clinical to virological
and molecular biological in nature. It should be noted that it is
difficult to correlate the in vivo effects of Tat with the effects of
Tat in experiments involving Tat transfection or purified Tat
protein conducted in cultured cells since it is not known how
the Tat concentration found in various tissues of HIV-1-
infected individuals compares to those found in transfected cell
is culture. This is an important caveat and care should be taken
before extrapolating conclusions from cell culture experiments
to pathogenesis in vivo. Nevertheless, research indicates that
the HIV-1 Tat protein plays a significant role in accelerating
viral-related pathologies such as Kaposi's sarcoma by affecting
both cellular and viral processes, e.g., cell cycle/cellular
morphology and HHV-8 reactivation, respectively. It has
been suggested that due to genome size constraint small
viruses such as HIV-1 must encode several functions in their
relatively few gene products (Jeang et al., 1999). The fact that
Tat can interact with an ever growing list of cellular and viral
processes in such diverse ways as discussed in this review
lends credence to this notion. Reciprocally, as shown in Figs. 1and 2, many of these viruses can enhance the replication and
pathogenesis of HIV-1. Finally, the fact that Tat expression has
so many disease manifestations makes Tat an attractive
therapeutic target protein.
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